Researchers from PMV Pharmaceuticals Inc. and collaborators described the effect of rezatapopt (PC-14586), a first-in-class selective p53 reactivator designed to reinstate p53 Y220C mutant function.

The paper titled, “Discovery of Rezatapopt (PC14586), a First-in-Class, Small-Molecule Reactivator of p53 Y220C Mutant in Development” can be accessed here. Announced a partnership with ...

The paper titled,“Discovery of Rezatapopt (PC14586), a First-in-Class, Small-Molecule Reactivator of p53 Y220C Mutant in Development” can be accessed here . Announced a partnership with ...

Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS ... therapies targeting p53, today reported ...

This marks Jacobio's successful transformation from the early R&D stage to an innovation-driven value realization stage," said Dr.Yinxiang Wang, the Chairman and CEO of Jacobio Pharma. "Looking ahead ...

HC Wainwright reissued their buy rating on shares of PMV Pharmaceuticals (NASDAQ:PMVP – Free Report) in a report released on Thursday morning,Benzinga reports. The firm currently has a $5.00 target ...

Excited to share our new tPRIME platform that powerfully drives gene transcription! p53 Y220C targeting is just the start. Contact us if interested in discussing the potential of this platform to ...